66 articles with PhotoCure
New article published in Urologic Oncology: Macro and Microeconomics of Blue Light Cystoscopy with Cysview in Non-Muscle Invasive Bladder Cancer
Photocure, The Bladder Cancer Company, announces the publication of a study in the journal Urologic Oncology.
Photocure: Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)
Photocure ASA announces that its partner Asieris Pharmaceuticals has administered the first European patient in its phase III clinical trial for APL-1702.
Photocure ASA, The Bladder Cancer Company, announces that President and Chief Executive Officer, Daniel Schneider and Chief Financial Officer, Erik Dahl are scheduled to present corporate overviews at two upcoming institutional investor conferences in June.
Photocure ASA, the Bladder Cancer Company, reported Hexvix®/Cysview® revenues of NOK 81.6 million in the first quarter of 2021, and EBITDA of NOK 18.1 million, following the continued successful launch in markets previously operated by Ipsen Pharma SAS.
Photocure announces Hexvix regulatory filing accepted for review in Chile with Fast Track designation
Photocure ASA, the Bladder Cancer Company, announces that notification was given to its partner and exclusive distributor, Genotests SpA by the Instituto de Salud Pública de Chile that the Marketing Authorization Application for Hexvix® has been accepted for regulatory review.
Photocure ASA, the Bladder Cancer Company, announces the publication of its sustainability report for 2020, renewing its commitment to transparency, corporate governance principles, sustainability and business ethics.
Photocure ASA reports Hexvix®/Cysview® revenues of NOK 97.7 million in the fourth quarter of 2020.
Asieris and Photocure Expand Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan
Asieris Pharmaceuticals announced that the company has entered into a license agreement with Photocure ASA to exclusively register and commercialize Hexvix® in Mainland China and Taiwan.
Photocure ASA : The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients, announces that it has entered into a partnership agreement with Asieris MediTech Co., Ltd., a division of Jiangsu Yahong Meditech Co., Ltd., whereby Asieris has obtained exclusive rights to register and commercialize Hexvix® in Mainland China and Taiwan.
Photocure ASA announced new data and analyses presented at the 21st Annual Meeting of the Society of Urologic Oncology.
Photocure ASA reported Hexvix®/Cysview® revenues of NOK 49.6 million in the third quarter of 2020, with the U.S. market continuing the COVID-19 rebound with a growth of 20%.
Photocure ASA announces a highlight from the BLADDR 2020 congress, a poster presentation on new findings from the Nordic Flexible BLC registry, an ongoing prospective multicenter study.
Photocure ASA announces that the European Patent Office has granted patent EP 2983780 covering the commercial Cevira® device in Europe until 2034.
Photocure ASA announces the commencement of the sales, marketing and distribution of Hexvix® in the European markets formerly operated by Ipsen Pharma SAS.
Photocure ASA reported Hexvix®/Cysview® revenues of 53.5 million in the second quarter of 2020, corresponding to growth of three per cent, despite a significant Covid-19 impact in the beginning of the quarter in the U.S.
Photocure ASA, announced the appointment of Genotests SpA as the exclusive distributor for the commercialization of Hexvix® in Chile.
Reference is made to the OSE notification 27 April 2020 from Photocure ASA regarding the return of Hexvix® sales, marketing and distribution rights in Europe and other markets currently controlled by Ipsen Pharma SAS.
Photocure ASA (OSE: PHO), held its annual general meeting on 10 June 2020 at 17:00 hours (CET). All proposals were resolved as presented in the notice convening the annual general meeting dated 19 May 2020 , as further set out in the minutes from the general meeting attached hereto. For further information, please contact:
Photocure ASA announces the company's first sustainability report, which will be presented at the Annual General Meeting at 17:00 CET.
Photocure ASA announced key data was published by the 2020 American Urological Association Annual Virtual Meeting.